EMA Grants Conditional Approval for Daraxonrasib in KRAS G12C Metastatic Pancreatic Cancer
The European Medicines Agency approved daraxonrasib last Wednesday for metastatic pancreatic cancer with a KRAS G12C mutation, opening the first targeted oral therapy for a disease that kills most patients within a year.
- Median overall survival doubled to 13.2 months from 6.6 months in heavily pretreated patients.
- One-year survival reached 53.2 percent versus 17 percent with standard chemotherapy.
- Belgian reimbursement negotiations with RIZIV may take up to 16 months at a list price of €38,000 per month.
Pancreatic cancer remains one of the deadliest malignancies, with a five-year survival rate of roughly 13 percent compared with 71 percent for colorectal cancer, oncologist Amy de Haar-Holleman of UZ Brussel told HBVL. “In 2030 only lung cancer will cause more deaths, according to current projections,” she said. Over the past decades, little progress has been made in treatment, she added.
The EMA followed with conditional marketing authorization last week. “This is truly a breakthrough,” de Haar-Holleman told HBVL. “People are really jumping for this.”
In the key study group, median overall survival reached 13.2 months with daraxonrasib versus 6.6 months with standard-of-care chemotherapy. At 12 months, 53.2 percent of patients on the KRAS inhibitor were alive compared with 17 percent on chemotherapy. Tumor assessments showed no detectable cancer in one of 12 patients during early follow-up. “That is a really beautiful story,” de Haar-Holleman said.
The drug inhibits the mutant KRAS G12C protein that drives uncontrolled cell division in approximately 1 to 2 percent of pancreatic adenocarcinomas. “In more than 90 percent of people with pancreatic cancer there is a KRAS mutation that keeps the cancer cell dividing,” de Haar-Holleman told HBVL. “This drug works on that faulty protein and hits the brakes so the division stops.”
Unlike cytotoxic chemotherapy, which damages mucosal linings and blood counts, daraxonrasib targets the oncogenic driver directly. “With chemotherapy the mucous membranes break down and blood cells deteriorate,” de Haar-Holleman said. “This agent works in a targeted way. In a smart manner it hits the cancer cell so that it stops dividing or dies.”
Belgium must now negotiate reimbursement with the manufacturer, Mirati Therapeutics, a process de Haar-Holleman estimates at eight to 16 months. “The clinical added value will be evident for RIZIV; that will not be a problem,” she told HBVL. “The price is where it pinches. The medicine you take daily costs €38,000 per month.”
While negotiations proceed, the company may supply the drug through a compassionate-use program. “Because people are really waiting for this,” de Haar-Holleman told HBVL.
In several Belgian hospitals, including UZ Brussel, patients are enrolling in a follow-up study examining whether treatment-naive patients benefit most from the pill alone or whether chemotherapy remains the better option.
Durability remains uncertain. The trial tracked patients for a maximum of 15 months. “We expect efficacy to wane over time in most patients,” de Haar-Holleman told HBVL. “Usually a tumor eventually escapes the drug by adapting itself. There is unfortunately no targeted therapy that works lifelong in all patients. The ongoing research will clarify that further.”
The European Medicines Agency, founded in 1995 after more than seven years of negotiations among EU governments, replaced the Committee for Proprietary Medicinal Products and the Committee for Veterinary Medicinal Products. It operated from London until relocating to Amsterdam in March 2019 following the United Kingdom’s withdrawal from the European Union.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
Keep reading
- OpenAI Reportedly Taps FIH Mobile for AI Smartphone Assembly, Luxshare for Components
- Low-Grade Appendiceal Mucinous Neoplasm Masquerading as Acute Appendicitis: Diagnostic Challenges, Surgical Management, and Surveillance Strategies
- Pope Leo XIV Cleared for South America Tour After Lung Cancer Surgery (newsdirectory3.com)
- ctDNA Status Predicts SBRT Benefit in Oligoprogressive Prostate Cancer (newsy-today.com)